ScripRoche has unveiled promising Phase Ib/IIa trial results suggesting its “brain shuttle” Alzheimer’s disease candidate trontinemab could be safer and more effective than approved therapies, and will beg
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its
Generics BulletinOrganon believes there is “considerable growth potential” for the Tofidence (tocilizumab-bavi) biosimilar to Genentech’s Actemra, after acquiring rights in the US for the product from Biogen, in a dea
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C